Dana-Farber Trial Lifts Pancreatic Tumor Response to 42% From 9% With Paricalcitol
Updated
Updated · BIOENGINEER.ORG · May 26
Dana-Farber Trial Lifts Pancreatic Tumor Response to 42% From 9% With Paricalcitol
6 articles · Updated · BIOENGINEER.ORG · May 26
Thirty-six patients with previously untreated metastatic pancreatic cancer received gemcitabine and nab-paclitaxel with paricalcitol or placebo in a randomized Dana-Farber trial published in Nature Cancer.
Paired biopsies showed the vitamin D receptor agonist reprogrammed cancer-associated fibroblasts without reducing their numbers, loosening the fibrotic, immunosuppressive stroma and increasing cytotoxic T-cell infiltration.
Paricalcitol was broadly safe, though some oral-dose patients developed manageable hypercalcemia; the study was designed for safety rather than definitive efficacy.
Even so, the paricalcitol groups posted a 42% partial response rate versus 9% with placebo and better one-year progression-free survival.
High pretreatment VDR expression tracked with better outcomes, pointing to a biomarker-led strategy for larger trials and possible combinations with immunotherapy.
Could a blood test reveal a tumor's ecosystem, guiding this new vitamin D therapy?
Beyond pancreatic cancer, could this strategy dismantle the defenses of other notoriously tough tumors?
Vitamin D Analog Paricalcitol Shows Promise in Overcoming Therapeutic Resistance in Metastatic Pancreatic Cancer: Insights from 2026 Dana-Farber Trial
Overview
On May 25, 2026, a Dana-Farber clinical trial led by Kimberly Perez revealed a major breakthrough in metastatic pancreatic cancer treatment. The study showed that Paricalcitol, a synthetic vitamin D analog, can overcome therapeutic resistance by remodeling the tumor’s dense stroma. This is important because the tough tumor microenvironment usually blocks drug delivery and reduces treatment effectiveness. By targeting these stromal components, Paricalcitol creates a more open environment, allowing other therapies to work better and improving patient outcomes. This discovery marks a significant step forward in the fight against this aggressive cancer.